PRF1 and neoplasm: The absence of PRF1 may activate immune checkpoint pathways, such as the PD-1/PD-L1 pathway, leading to inactivation of T cells, reduced proliferation, and increased apoptosis, thus impairing their ability to recognize and attack tumor cells [16].